m6A modification: recent advances, anticancer targeted drug discovery and beyond

LJ Deng, WQ Deng, SR Fan, MF Chen, M Qi, WY Lyu… - Molecular cancer, 2022 - Springer
Abstract Abnormal N6-methyladenosine (m6A) modification is closely associated with the
occurrence, development, progression and prognosis of cancer, and aberrant m6A …

RNA modifications: importance in immune cell biology and related diseases

L Cui, R Ma, J Cai, C Guo, Z Chen, L Yao… - Signal transduction and …, 2022 - nature.com
RNA modifications have become hot topics recently. By influencing RNA processes,
including generation, transportation, function, and metabolization, they act as critical …

Insight into the structure, physiological function, and role in cancer of m6A readers—YTH domain-containing proteins

J Liao, Y Wei, J Liang, J Wen, X Chen, B Zhang… - Cell death …, 2022 - nature.com
Abstract YT521-B homology (YTH) domain-containing proteins (YTHDF1-3, YTHDC1-2) are
the most crucial part of N6-methyladenosine (m6A) readers and play a regulatory role in …

PRMT1 methylation of WTAP promotes multiple myeloma tumorigenesis by activating oxidative phosphorylation via m6A modification of NDUFS6

Y Jia, X Yu, R Liu, L Shi, H Jin, D Yang, X Zhang… - Cell Death & …, 2023 - nature.com
Epigenetic modifications play important roles during the pathogenesis of multiple myeloma
(MM). Herein, we found that protein arginine methyltransferase 1 (PRMT1) was highly …

N6-methyladenosine demethylase FTO suppressed prostate cancer progression by maintaining CLIC4 mRNA stability

L Zou, W Chen, X Zhou, T Yang, J Luo, Z Long… - Cell Death …, 2022 - nature.com
The fat mass and obesity-associated protein (FTO) is an N6-Methyladenosine (m6A)
demethylase, which has been revealed to play critical roles in tumorigenesis. However, its …

Crosstalk between m6A regulators and mRNA during cancer progression

X Niu, Y Yang, Y Ren, S Zhou, Q Mao, Y Wang - Oncogene, 2022 - nature.com
Abstract m6A modification, the most abundant and widespread RNA modification, is present
and involved in the occurrence and development of various cancers. To date, most studies …

FTO inhibits epithelial ovarian cancer progression by destabilising SNAI1 mRNA through IGF2BP2

M Sun, X Zhang, F Bi, D Wang, X Zhou, X Li, Q Yang - Cancers, 2022 - mdpi.com
Simple Summary Ovarian cancer is the gynaecologic malignant tumour with the highest
mortality. Most patients are already in the advanced stage when they are found, and the 5 …

N6‐methyladenosine (m6A) modification in gynecological malignancies

C Zhang, N Liu - Journal of cellular physiology, 2022 - Wiley Online Library
Abstract N6‐methyladenosine (m6A) modification is one of the most abundant modifications
in eukaryotic mRNA, regulated by m6A methyltransferase and demethylase. m6A modified …

Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance …

M Ye, J Chen, F Lu, M Zhao, S Wu, C Hu, P Yu, J Kan… - Cell & Bioscience, 2023 - Springer
Abstract Background N6-methyladenosine (m6A) modification is the most abundant
reversible methylation modification in eukaryotes, and it is reportedly closely associated with …

Interplay between m6A epitranscriptome and epigenome in cancer: current knowledge and therapeutic perspectives

G Bove, S Amin, M Babaei, R Benedetti… - … Journal of Cancer, 2023 - Wiley Online Library
Chromatin has an extremely flexible structure that allows the fine regulation of gene
expression. To orchestrate this process, small chemical modifications are dynamically …